Consolidated revenue was $75.3 million in the current year quarter, an increase of approximately $8.3 million, or 12%, over the third quarter of fiscal 2008. Reagent price increases and increased instrument revenue in the United States market as well as increased sales of reagents outside of the U.S. accounted for the majority of the revenue increase. Revenue in the quarter was negatively impacted by approximately $1.7 million from foreign currency translation as compared with the third quarter of fiscal 2008.
Consolidated gross margin was $53.8 million, or 71.4% of revenue, in the current year quarter compared with $48.3 million, or 72.1% of revenue, in the prior year quarter. Consolidated gross margin was negatively impacted by higher than normal manufacturing variances, which included the disposal of certain inventory related to our transfer of production from Houston to Norcross, Ga.
Operating expenses for the third quarter increased approximately $5.2 million, or 27%, over the prior year quarter primarily attributable to the BioArray acquisition as well as the Company's initiative to sell its products directly to the end user in the French and the United Kingdom markets.
Summary of Instrument Orders
Q3 2009 Orders Cumulative Instrument N.A.(1
|SOURCE Immucor, Inc.|
Copyright©2009 PR Newswire.
All rights reserved